Annovis Bio, Inc. (ANVS) SEC filings

ANVSNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30

$0.93+0.08 (+9.31%)

Close on Nov 13, 2026Market cap $39.46MP/E –Yield –

SEC filings

40 of Annovis Bio's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 13, 2026	SEC EDGAR
Current report	8-K	Nov 13, 2026	Nov 13, 2026	SEC EDGAR
Current report	8-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Nov 4, 2026	Nov 4, 2026	SEC EDGAR
Current report	8-K	Nov 3, 2026	Nov 4, 2026	SEC EDGAR
Current report	8-K	Oct 29, 2026	Oct 30, 2026	SEC EDGAR
Current report	8-K	Oct 19, 2026	Oct 20, 2026	SEC EDGAR
Proxy statement	DEF 14A	Oct 14, 2026	Sep 11, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 14, 2026	SEC EDGAR
Current report	8-K	Aug 14, 2026	Aug 14, 2026	SEC EDGAR
Current report	8-K	Jul 7, 2026	Jul 10, 2026	SEC EDGAR
Current report	8-K	Jun 17, 2026	Jun 17, 2026	SEC EDGAR
Current report	8-K	May 20, 2026	May 20, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 15, 2026	SEC EDGAR
Current report	8-K	May 15, 2026	May 15, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 17, 2026	Apr 30, 2026	SEC EDGAR
Current report	8-K	Apr 9, 2026	Apr 10, 2026	SEC EDGAR
Current report	8-K	Mar 23, 2026	Mar 25, 2026	SEC EDGAR
Current report	8-K	Mar 16, 2026	Mar 16, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 13, 2026	SEC EDGAR
Current report	8-K	Feb 12, 2026	Feb 12, 2026	SEC EDGAR
Current report	8-K	Jan 28, 2026	Jan 28, 2026	SEC EDGAR
Current report	8-K	Nov 12, 2025	Nov 13, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Oct 26, 2025	Oct 28, 2025	SEC EDGAR
Current report	8-K	Oct 10, 2025	Oct 14, 2025	SEC EDGAR
Current report	8-K	Sep 25, 2025	Sep 29, 2025	SEC EDGAR
Current report	8-K	Aug 11, 2025	Aug 15, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 12, 2025	SEC EDGAR
Current report	8-K	Aug 12, 2025	Aug 12, 2025	SEC EDGAR
Current report	8-K	Jun 17, 2025	Jun 23, 2025	SEC EDGAR
Current report	8-K	Jun 19, 2025	Jun 20, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 13, 2025	SEC EDGAR
Current report	8-K	May 9, 2025	May 13, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 17, 2025	Apr 30, 2025	SEC EDGAR
Current report	8-K	Mar 26, 2025	Mar 27, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 21, 2025	SEC EDGAR
Current report	8-K	Mar 21, 2025	Mar 21, 2025	SEC EDGAR
Current report	8-K	Feb 5, 2025	Feb 5, 2025	SEC EDGAR
Current report	8-K	Feb 3, 2025	Feb 5, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Annovis Bio's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ANVS.

Compare: ANVS vs ACIU · ANVS vs BIVI · ANVS vs CRVO · ANVS vs ANRO · ANVS vs PMN

Company	Revenue	Growth
ACIU	CHF 3.94M	–
CRVO	$8.73K	-99.9%
ANVS	$0	–
BIVI	–	–
ANRO	–	–
PMN	–	–

Company

Next earnings (est.): Mar 15, 2027, after close
Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 8
Held by institutions: 25.5%
Auditor: Ernst & Young LLP
SEC CIK: 1477845

Advertisement
300 × 250

See a number that looks wrong?